AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 141 min read

HC Wainwright & Co. reiterates Buy rating on Biomea Fusion, $4 price target

HC Wainwright & Co. reiterated a Buy rating and $4 price target for Biomea Fusion, implying a 217.5% upside from the Oct 13 close. The analyst cited positive clinical trial developments, including promising results from the OPAL study and encouraging Phase 1 data for BMF-650, as reasons for the rating.

Original reporting
tradingview.com
Published Oct 14, 2026, 10:21 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 10:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HC Wainwright & Co. reiterates Buy rating on Biomea Fusion, $4 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The $4 target dramatically raises the valuation, likely prompting short covering and new buying.

02

Market read

Analyst upgrade with a high price target provides a clear short‑term catalyst for BFM.

03

What to watch

Potential regulatory hurdles and the need for later‑stage trial data could temper upside.

Relevance 6/10Novelty 5/10Timing: today

Background

HC Wainwright is a boutique research firm; its notes often move small‑cap biotech stocks.

Market effects

Sector

Positive signal may lift other early‑stage biotech stocks in the obesity/GLP‑1 space.

Regional

Limited to U.S. biotech sector; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

The upgrade may be premature given the data are still pre‑clinical; risk of overvaluation.

Key entities

  • company
    Biomea Fusion

    Biotech developing obesity and GLP‑1 therapies.

  • analyst
    HC Wainwright & Co.

    Research firm that issued the Buy rating.

Read at source← All news

Related articles

OCT 14
$BMEALowAI 8/10

Citizens reiterates Biomea Fusion stock rating on Phase 1 data

Citizens reiterated a Market Outperform rating and $7.00 price target on Biomea Fusion (BMEA) after Phase 1 data for BMF-650 showed promising results. The stock trades at $1.26, with analyst targets ranging from $4 to $10. Biomea completed enrollment in a Phase II diabetes trial, with results expected in Q1 2027. Brookline Capital Markets initiated coverage with a Buy rating and $10.00 target. The company canceled a planned public offering due to market conditions.

investing.com2 min
OCT 14
$BMEAMedAI 8/10

What’s Going On With Biomea Fusion (BMEA) Stock After Hours? - Biomea Fusion (NASDAQ:BMEA)

Biomea Fusion (BMEA) shares dropped 28.58% to $0.90 in after-hours trading after announcing Phase 1 results for BMF-650, its weight management drug. Mean weight reduction ranged from 1.5% to 6.1% across cohorts, with no severe adverse events reported. The company plans further analysis and potential partnerships. BMEA has a market cap of $91.33M and fell 7.35% to $1.26 during regular trading.

benzinga.com2 min